# Study on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction

Study · id `cardio:ct-nct04695990` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04695990](<https://clinicaltrials.gov/study/NCT04695990>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04695990

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04695990. Randomized; no masking; primary purpose treatment. Start 2021-01-15 (anticipated); primary completion 2022-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04695990, source copy `cardio:ctgov-nct04695990-2021-01-06`, retrieved 2026-10-26)
- Planned start: 2021-01-15 (anticipated) (ClinicalTrials.gov record NCT04695990, source copy `cardio:ctgov-nct04695990-2021-01-06`, retrieved 2026-10-26)
- Primary completion: 2022-03-01 (anticipated) (ClinicalTrials.gov record NCT04695990, source copy `cardio:ctgov-nct04695990-2021-01-06`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT04695990, source copy `cardio:ctgov-nct04695990-2021-01-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04695990-2021-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction
- Condition: Heart Failure
- Condition: Myocardial Infarction
- Intervention (Drug): Wenyang Huoxue Decoction
- Intervention (Drug): Wenyang Huoxue placebo
- Lead sponsor: Jun Li
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Jun Li (`cardio:org-jun-li`)

## Provenance

Content hash: 3222c043b8835de40c3ffd6f7e0c514632887d2b3b6a1dd7de755e6b11684b2d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
